Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Biomarkers in Oncology | Access and Reimbursement | US | 2018

Login to access report north_east
Contact sales account_box

Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small-cell lung cancer, malignant melanoma, and colorectal cancer. While biomarker-associated therapies offer the advantage of selecting the patients most likely to respond to treatment, these therapies are premium-priced and often subject to payer restrictions. We explore the drivers and barriers to use of these agents and report on how reimbursement impacts drug selection and prescribing. We also evaluate surveyed medical oncologists’ and surveyed payers’ perceptions of emerging biomarker-driven therapies in select solid-tumor indications.

Questions Answered:

  • What factors most greatly influence payers’ reimbursement decisions for biomarker-driven therapies in NSCLC, malignant melanoma, and colorectal cancer? What restrictions do they impose?
  • Do access and reimbursement challenges differ by indication and/or how well established is the biomarker in each indication?
  • What role do reimbursement, cost, and clinical factors play in oncologists’ decisions to prescribe biomarker-driven therapies.
  • What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?
  • What factors influence reimbursement and access for companion biomarker tests?

Product Description:

Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Scope of Report:

  • Geography: United States.
  • Primary research: Survey of 101 medical oncologists in the United States and survey of 30 U.S. managed care organizations (MCO) pharmacy and medical directors (PDs/MDs).
  • Key drugs covered: Keytruda, Xalkori , Zykadia, Gilotrif, Tagrisso, Portrazza, Zelboraf, Tafinlar, Cotellic, Mekinist, Avastin, Erbitux, Vectibix.
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
north_east
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
north_east
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
north_east
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east